Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Antengene raises $120mm in Series B round

Executive Summary

Antengene Corp. (cancer and infectious disease drug development) raised $120mm through its Series B round. Boyu Capital and FountainVest led and were joined by Celgene, Wuxi Corporate Venture Fund, and Taikang, along with returning backers Qiming Venture Partners and TF Capital. Proceeds will support continued development of lead projects ATG008, a second generation TORC1/2 inhibitor in-licensed from Celgene and in Phase II for HBV+ hepatocellular carcinoma, and ATG010 (selinexor), in Phase III for blood and solid tumors including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, and glioblastoma. The company previously raised $21mm in its 2017 Series A round.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register